β-Amyloid Aggregation Assay Using Polysulfides for Drug Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods are inadequate for effectively screening potential therapeutic agents that prevent or reduce β-amyloid fragment peptide aggregation, which is a key factor in Alzheimer's Disease progression.
Innovation Solution
An in vitro drug screening method using a reaction mixture comprising β-amyloid fragment peptides, polysulfides, and test candidates, followed by detection of aggregation through immunoassays, mass spectrometry, or other techniques, to identify candidates that inhibit aggregation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current screening methods are used, then screening can be performed, but the effectiveness in identifying therapeutic agents that prevent β-amyloid aggregation is inadequate
Solution Approach 1:
The patent modifies the chemical environment parameters by introducing polysulfides (Na2S, Na2S2, Na2S3, Na2S4) and controlling pH levels to create optimal conditions for β-amyloid aggregation. This parameter change enables more effective screening by establishing a reaction environment that promotes aggregation, making it easier to identify compounds that prevent it
Solution Approach 2:
The patent uses polysulfides as intermediary substances that facilitate the aggregation process. These intermediaries act as catalysts or mediators in the aggregation reaction, allowing test candidates to be screened more effectively by their ability to interfere with the polysulfide-mediated aggregation pathway
2Measurement precision
If multiple detection techniques are employed, then measurement accuracy improves, but assay complexity increases
Solution Approach 1:
The patent designs a multi-functional assay system that can be detected by multiple techniques (immunoblot, mass spectrometry, ultracentrifugation, size-exclusion chromatography, dynamic light scattering). Each detection method serves multiple purposes: confirming aggregation, characterizing aggregate size, and validating results across different analytical approaches, thereby improving measurement precision without proportionally increasing complexity
Data Source
AI summary
The present invention is directed to a protein aggregation assay, and methods of use thereof.